Drug to slow early-stage Alzheimer's disease approved by Health Canada
Lecanemab is the first medication approved in Canada that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of Alzheimer’s disease.
Get latast news super fast
